New REDUCE-IT Analyses Show VASCEPA /VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsGlobe Newswire • 20 days ago
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the...
Share to Feed
Company's IP Protection for VAZKEPA in Europe Now Extended Into 2039DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced...
Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about...
Amarin Co. plc (NASDAQ:AMRN Free Report) Zacks Research boosted their Q1 2024 earnings per share (EPS) estimates for Amarin in a research report issued to clients and investors on...
-- Subgroup Analyses from REDUCE-IT and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024...
Amarin Co. plc (NASDAQ:AMRN Free Report) Investment analysts at Cantor Fitzgerald raised their FY2024 earnings estimates for Amarin in a note issued to investors on Monday, March...
Related Stocks: NAS:AMRN...
-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 ---- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash...
Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript...
Amarin Co. plc (NASDAQ:AMRN Get Free Report) traded up 9.9% on Tuesday . The company traded as high as $1.34 and last traded at $1.33. 1,111,735 shares traded hands during mid-day trading, a...